Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$21.03 -2.0%	$23.23	$15.34 ▼ $26.58	$2.62B	0.66	1.14 million shs	1.23 million shs
GYRE Gyre Therapeutics	$7.21 -2.4%	$8.61	$6.11 ▼ $19.00	$692.87M	1.72	130,296 shs	52,959 shs
PTGX Protagonist Therapeutics	$55.48 -1.7%	$51.29	$32.50 ▼ $60.60	$3.44B	2.26	841,144 shs	471,125 shs
SWTX SpringWorks Therapeutics	$46.99	$46.74	$28.21 ▼ $62.00	$3.54B	0.68	2.64 million shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	-1.96%	-3.58%	-7.80%	-6.62%	+24.44%
GYRE Gyre Therapeutics	-2.44%	-3.74%	-13.45%	-18.81%	-52.41%
PTGX Protagonist Therapeutics	-1.70%	+4.68%	+2.89%	+19.88%	+54.45%
SWTX SpringWorks Therapeutics	0.00%	0.00%	+0.45%	+24.02%	+20.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.8986 of 5 stars	3.6	1.0	3.9	2.9	3.3	3.8
GYRE Gyre Therapeutics	0.0313 of 5 stars	0.0	1.0	0.0	0.6	0.8	0.0
PTGX Protagonist Therapeutics	1.4772 of 5 stars	2.5	1.0	0.0	3.4	2.5	0.0
SWTX SpringWorks Therapeutics	1.5183 of 5 stars	3.1	2.0	0.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	56.13% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	19.14% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.88% Upside

Current Analyst Ratings Breakdown

Latest GYRE, SWTX, PTGX, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/12/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$47.00 ➝ $47.00
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00
4/29/2025	SWTX SpringWorks Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
4/29/2025	SWTX SpringWorks Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$66.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$77.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	SWTX SpringWorks Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$63.00 ➝ $47.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$534.65M	4.80	$2.40 per share	8.77	$6.10 per share	3.45
GYRE Gyre Therapeutics	$100.64M	6.72	$0.19 per share	37.42	$1.05 per share	6.87
PTGX Protagonist Therapeutics	$207.80M	16.55	$4.44 per share	12.49	$11.33 per share	4.90
SWTX SpringWorks Therapeutics	$191.59M	18.48	N/A	N/A	$6.47 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.57	13.39	9.87	0.87	36.91%	42.45%	36.59%	8/6/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.02	360.68	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	73.97	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)

Latest GYRE, SWTX, PTGX, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	N/A	N/A	N/A	$30.80 million	N/A
8/6/2025	Q2 2025	CPRX Catalyst Pharmaceuticals	$0.57	N/A	N/A	N/A	$140.42 million	N/A
8/6/2025	Q2 2025	SWTX SpringWorks Therapeutics	-$0.81	N/A	N/A	N/A	$73.39 million	N/A
8/5/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	N/A	N/A	N/A	$8.32 million	N/A
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.14	5.96
GYRE Gyre Therapeutics	N/A	3.60	3.19
PTGX Protagonist Therapeutics	N/A	17.25	17.26
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
GYRE Gyre Therapeutics	23.99%
PTGX Protagonist Therapeutics	98.63%
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
GYRE Gyre Therapeutics	10.00%
PTGX Protagonist Therapeutics	4.90%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	121.98 million	109.29 million	Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

GYRE, SWTX, PTGX, and CPRX Headlines

Recent News About These Companies

European Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 Patients

July 18 at 12:35 PM | quiverquant.comQ

SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

July 18 at 12:35 PM | quiverquant.comQ

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18 at 11:30 AM | globenewswire.com

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18 at 11:30 AM | globenewswire.com

SpringWorks Therapeutics (NASDAQ:SWTX) Receives $52.57 Consensus Price Target from Brokerages

July 17 at 3:41 AM | americanbankingnews.com

SpringWorks Therapeutics (NASDAQ:SWTX) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

July 17 at 2:09 AM | americanbankingnews.com

Principal Financial Group Inc. Trims Stake in SpringWorks Therapeutics (NASDAQ:SWTX)

July 7, 2025 | marketbeat.com

37,543 Shares in SpringWorks Therapeutics (NASDAQ:SWTX) Bought by CIBRA Capital Ltd

July 2, 2025 | marketbeat.com

SpringWorks Therapeutics Completes Merger and Delisting

July 1, 2025 | tipranks.com

SpringWorks Therapeutics Inc (SWTX) - Investing.com

June 28, 2025 | investing.com

AMI Asset Management Corp Purchases 10,849 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 26, 2025 | marketbeat.com

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat

June 24, 2025 | msn.com

SG Americas Securities LLC Buys 9,409 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 21, 2025 | marketbeat.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

June 20, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

June 20, 2025 | globenewswire.com

GAMMA Investing LLC Buys 13,270 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 19, 2025 | marketbeat.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 26, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE, SWTX, PTGX, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.03 -0.42 (-1.96%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.32 +0.29 (+1.38%)

As of 07/18/2025 07:35 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Gyre Therapeutics NASDAQ:GYRE

$7.21 -0.18 (-2.44%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.38 +0.17 (+2.36%)

As of 07/18/2025 06:43 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Protagonist Therapeutics NASDAQ:PTGX

$55.48 -0.96 (-1.70%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$53.00 -2.48 (-4.47%)

As of 07/18/2025 07:27 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)

As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time